BCL2 and acute myeloid leukemia: In the broader AML population, the incorporation of the BCL-2 inhibitor venetoclax (see below) has been explored in combination with reduced-dose chemotherapy (i.e., 2+5 regimen) [71], and with fludarabine- or cladribine-based regimes [72,73,74], although in the latter studies only a few older patients were included.